Past CureTalks
Off-the-shelf Immune Drug for Aggressive Multiple Myeloma: Teclistamab
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma. This follows a PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA) received earlier this year. …
Birth Control Pills in PCOS Treatment – Benefits, Risks & All You Need to Know
Birth control pills or oral contraceptive pills (OCP) can be used for long-term treatment in women with PCOS who are not planning pregnancy. These pills have been shown to help regulate many PCOS symptoms such as irregular periods, extra hair…
Lung Cancer Mutations and Treatment Advances
Lung cancer, the most common cancer type with the highest mortality, can largely be categorized by the genetic mutations that cause it. By targeting the specific genetic mutation behind a patient’s cancer, targeted therapies have enabled increasing numbers of patients…
Goals and challenges of developing a patient focused myeloma center of excellence
The multiple myeloma treatment field has undergone several changes over the past 10-20 years. The average overall survival has changed from 1-3 years to 10-20 years. Yet, there is no established curative therapy for multiple myeloma. However, advanced monitoring with…
Prevention and Management of PCOS Related Infertility – A Q&A Session
Polycystic ovary syndrome (PCOS) is a chronic disorder affecting 1 in 10 women of reproductive age. It is the primary cause of reduced frequency of ovulation and anovulation at the reproductive age and is commonly associated with infertility. The prevalence…